ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 146

The Treatment of Acute Gouty Arthritis in Complex Hospitalized Patients with Anakinra

Mary Bach1, Jane Park1, Pradipta Ghosh1, Peter A. Simkin2 and Gregory C. Gardner3, 1Rheumatology, University of Washington, Seattle, WA, 2Div of Rheumatology, University of Washington, Seattle, WA, 3Medicine/Rheumatology, University of Washington, Seattle, WA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Anakinra and gout

  • Tweet
  • Email
  • Print
Session Information

Title: Metabolic and Crystal Arthropathies

Session Type: Abstract Submissions (ACR)

Background/Purpose: The management of acute crystal-induced arthritis in the hospital setting may be a difficult clinical problem due to co-morbidities that limit the use of traditional treatment options.  Anakinra, an anti-IL1 receptor antagonist, has been successful in the treatment of acute/chronic gout in 3 published series and 4 case reports totaling 27 patients and 2 case reports of calcium pyrophosphate dihydrate (CPPD) disease.  We have previously reported our experience with 17 medically complex patients (16 gout, 1 CPPD) who had received 24 courses of anakinra which successfully treated their acute arthritis.  The purpose of this study is to add additional case experience in the use of anakinra in this same population.

Methods: We reviewed our consult records over the past 5 years to identify inpatients with acute crystal-induced arthropathy treated with anakinra.  Data extracted from the charts included age, gender, BMI, co-morbidities, uric acid level, joint(s) and soft-tissue sites involved, anakinra dosing, time to initial improvement, time to complete resolution of signs and symptoms of inflammation, and any possible side effects (i.e. infection or leukopenia).

Results: Twenty-six patients who had received 40 courses of anakinra were identified.  Eighteen patients had failed colchicine and/or steroids, and an additional 8 patients were felt not to be candidates for traditional therapy due to co-morbid disease.  None of the patients were candidates for NSAID therapy.  In 29 of the 40 episodes, the arthritis was polyarticular.  Foot and ankle joints were most commonly affected (44.5%) followed by hand and wrist (25%), knees (18.5%), shoulders, elbows and tendons (12%).  Following first dose of anakinra, 67.5% of patients demonstrated significant pain improvement within 24 hours and 85% had significant relief by 48 hours.  Complete resolution of signs and symptoms of gout occurred by day 5 in 72.5%. Seven patients received up to 5 courses with no apparent decrement in response. Anakinra was well–tolerated and no adverse outcomes were attributed to the drug.  Only one patient appeared to be refractory to this form of IL-1 inhibition.

Conclusion: Anakinra is an effective and safe alternative treatment for acute gouty arthritis in medically complex patients who fail or cannot undergo more conventional therapy


Disclosure:

M. Bach,
None;

J. Park,
None;

P. Ghosh,
None;

P. A. Simkin,
None;

G. C. Gardner,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-treatment-of-acute-gouty-arthritis-in-complex-hospitalized-patients-with-anakinra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology